- 11 studies on 4 new drugs including phase IIb of efpeglenatide to be presented
SEOUL, South Korea--(BUSINESS WIRE)--Hanmi Pharmaceutical Co., Ltd.(KSE: 128940) will present its 11 studies on 4 new drugs including the results of the phase IIb clinical trial of ‘efpeglenatide’ at the American Diabetes Association (ADA) 75th Scientific Sessions, taking place June 5 – 9, 2015, in Boston Convention Center, USA.
During the conference, Hanmi Pharmaceutical will announce the process of Quantum Project. The company will release the results of phase IIb clinical trials which include the long-acting (e.g. once-monthly treatment) and weight-loss effect of ‘efpeglenatide’. The company will also present its new drug ‘LAPSInsulin115’ which is under development as a once-weekly insulin formulation and ‘LAPS Insulin Combo’, the combination of ‘LAPSInsulin115’ and ‘efpeglenatide’.
Furthermore, Hanmi Pharmaceutical will provide the result of the phase I clinical trial on ‘LAPSGLP/GCG’, a novel long-acting GLP-1/Glucagon dual receptor agonist.
In total, 4 studies will be presented orally and other 7 studies will be presented on poster and paper.
The schedules for the presentations are as follows:
| 1. Efpeglenatide (LAPSCA-Exendin-4; HM11260C) | ||||||
| 1) Phase IIb clinical trial | ||||||
| HM-EXC-203 | : | Dose-Response Improvements in Glycemic Control and Body Weight Reductions with HM11260C, a Once Weekly GLP-1 Receptor Agonist with Liraglutide as reference, in Type 2 Diabetes (T2DM), oral presentation at 08:45 on Monday, June 8 | ||||
| HM-EXC-204 | : | Once a Month Treatment with HM11260C Improves Glycemic Control in Type 2 Diabetes (T2DM)–Interim Data from a 16-week Study, poster presentation at 12:00 on Sunday, June 7 | ||||
| HM-EXC-205 | : | Significant Effects of HM11260C on Body Weight over 20 weeks in Obese Subjects without Diabetes: a Randomized, Double-blind, Placebo controlled study, poster presentation at 12:00 on Sunday, June 7 | ||||
| 2) Phase I clinical trial | ||||||
| HM-EXC-102 | : | LAPSCA-Exendin-4 (HM11260C) Significantly Enhances Insulin Secretion and ß-cell Responsiveness in Subjects with Type 2 Diabetes Mellitus (T2DM), poster presentation at 11:30 on Saturday, June 6 | ||||
| HM-EXC-102 | : | Non-Inferior Delay in Gastric Emptying vs Lirgalutide and Favorable Glucometabolic Profile following treatment with LAPSCA-Exendin-4 (HM11260C) in Subjects with Type 2 Diabetes Mellitus (T2DM), publication only | ||||
| 3) Non-clinical trial | ||||||
| - | Superagonistic Mechanism of Increased Glucodynamic and Weight Loss Effects of LAPSCA-Exendin-4 (HM11260C), poster presentation at 11:30 on Saturday, June 6 | |||||
| 2. LAPSInsulin115 (HM12470) | ||||||
| 1) Phase I clinical trial | ||||||
| HM-INS115-101 | : | Use of PKPD Model to Design and Analyze Results of a Euglycemic Clamp study for a Very Long-Acting Insulin Analogue HM12470, poster presentation at 12:00 on Sunday, June 7 | ||||
| 2) Non-clinical trial | ||||||
| - | Unique Profile of the Weekly Insulin HM12470 : Very Slow Onset of Action, Rapid Off-rate Similar to Insulin, and Absence of Insulin Receptor Down Regulation, oral presentation at 14:30 on Saturday, June 6 | |||||
| 3. LAPSInsulin Combo (HM14220) | ||||||
| 1) Non-clinical trial | ||||||
| - | Once-weekly Combination of GLP-1R Agonist and Insulin (HM14220) Offers Improved Glycemic Control and Reduced Weight Gain Risk, oral presentation at 09:30 on Sunday, June 7 | |||||
| 4. LAPSGLP/GCG (HM12525A) | ||||||
| 1) Phase I clinical Trial | ||||||
| HM-OXM-101 | : | LAPSGLP/GCG Dual Agonist, HM12525A, Confirmed Prolonged Pharmacokinetics in Healthy Volunteers : A First-in-Human Phase I study, oral presentation at 09:45 on Sunday, June 7 | ||||
| 2) Non-clinical trial | ||||||
| - | A Novel Long-Acting GLP-1/Glucagon Dual Receptor Agonist : Potent Weight Loss Mechanism and Improvement of NASH by HM12525A, poster presentation at 11:30 on Saturday, June 6 | |||||
Hanmi Pharmaceutical Co., Ltd.
Hanmi Pharmaceutical is a Korea-based global pharmaceutical company focused on the development and commercialization of new pharmaceutical products. The Company is fully integrated from R&D through manufacturing, marketing and sales with an established presence in Korea as well as China. The Company invests over 20 percent of its sales in R&D and has over 20 programs in clinical development in three main areas: 1) novel long-acting biologics based on the Company’s LAPSCOVERY™ platform including weekly insulin, weekly to monthly GLP-1, and their combinations (Quantum Project) in diabetes and obesity; 2) novel targeted agents against cancer and autoimmune disorders; and 3) fixed-dose combination programs. More information on Hanmi is available at www.hanmipharm.com.
Contacts
Hanmi Pharmaceutical Co., Ltd.
Seung-woo Han / Eun-ryeong Jang, +82 2-410-0411
Communication Team
pa@hanmi.co.kr
Help employers find you! Check out all the jobs and post your resume.
